THE ROLE OF BIOMARKERS IN EARLY DISEASE DIAGNOSIS IN CLINICAL LABORATORY MEDICINE

***Uzoqova Bibisora** - cadet of the department of clinical laboratory diagnosis with the course of clinical laboratory diagnostics of PGD;*
***Nurmatova M.A.** - assistant of the department of clinical laboratory diagnosis with the course of clinical laboratory diagnostics of PGD;*
Samarkand state medical university Samarkand, Uzbekistan

Abstract. Biomarkers play a crucial role in modern clinical laboratory medicine, particularly in the early detection and monitoring of diseases. A biomarker is a measurable biological indicator that reflects normal biological processes, pathogenic processes, or responses to therapeutic interventions. With the advancement of laboratory technologies, biomarkers have become essential tools in diagnosing cardiovascular diseases, cancer, infections, and metabolic disorders at early stages.Early diagnosis significantly improves treatment outcomes and reduces morbidity and mortality rates. Laboratory-based biomarker testing provides rapid, accurate, and minimally invasive diagnostic information that supports clinical decision-making. This article discusses the classification of biomarkers, their clinical applications, and their importance in early disease detection and personalized medicine [1].

Keywords: Biomarkers, clinical laboratory medicine, early diagnosis, tumor markers, cardiac markers, inflammatory markers, personalized medicine.

In recent years, clinical laboratory medicine has become one of the most important pillars of modern healthcare. Accurate and timely laboratory results are essential for early disease detection, treatment monitoring, and prognosis evaluation. Among the various tools used in laboratory diagnostics, biomarkers have gained particular importance due to their ability to provide objective and measurable information about biological processes.A biomarker is defined as a measurable characteristic that indicates normal physiological processes, pathological changes, or responses to therapeutic interventions. Biomarkers can be detected in blood, urine, saliva, or other biological samples, making them practical and minimally invasive diagnostic tools [2].

The importance of early diagnosis cannot be overstated. Many diseases, such as cancer, cardiovascular disorders, and diabetes, may remain asymptomatic in their early stages. Biomarker testing enables clinicians to identify these conditions before clinical symptoms appear, allowing earlier intervention and improved patient outcomes.Advances in laboratory technologies, including immunoassays, molecular diagnostics, and automated analyzers, have significantly enhanced the sensitivity and specificity of biomarker detection. As a result, biomarkers are now central to evidence-based medicine and personalized healthcare strategies.Understanding the classification, applications, and limitations of biomarkers is essential for improving diagnostic accuracy and optimizing patient management in clinical practice [3].

Classification of Biomarkers.Biomarkers can be classified into several categories depending on their clinical purpose, biological function, and application in medical practice. Proper classification helps clinicians interpret laboratory results accurately and choose the most appropriate diagnostic and therapeutic strategies.

Diagnostic Biomarkers.Diagnostic biomarkers are used to detect or confirm the presence of a disease or medical condition. They help differentiate between healthy and pathological states. For example:Cardiac troponins (Troponin I and T) are used to diagnose acute myocardial infarction.Procalcitonin (PCT) helps distinguish bacterial infections from viral infections.D-dimer is used in the diagnosis of thromboembolic disorders.Diagnostic biomarkers are particularly valuable in emergency medicine, where rapid and accurate decision-making is critical.[4]

Prognostic Biomarkers.Prognostic biomarkers provide information about the likely course or outcome of a disease, regardless of treatment. They help predict disease progression, recurrence, or patient survival.Examples include-tumor markers such as CA-125 in ovarian cancer, which may indicate disease severity.B-type natriuretic peptide (BNP) levels in heart failure patients, which correlate with disease prognosis.Certain genetic mutations in oncology that indicate aggressive tumor behavior.Prognostic biomarkers assist physicians in identifying high-risk patients and adjusting monitoring strategies accordingly.[5,6]

Predictive Biomarkers.Predictive biomarkers indicate the likelihood of a patient responding to a specific treatment. They are essential in personalized and targeted therapy.For example:HER2 receptor status in breast cancer determines eligibility for trastuzumab therapy.EGFR mutations in lung cancer guide the use of targeted drugs.Pharmacogenetic markers that predict response to certain medications.These biomarkers improve treatment effectiveness and reduce unnecessary side effects.[7,8]

Monitoring Biomarkers.Monitoring biomarkers are used to assess disease progression or response to treatment over time.Examples include-HbA1c for long-term glucose control in diabetes.Viral load measurements in HIV and hepatitis infections.PSA levels for monitoring prostate cancer therapy.Regular measurement of monitoring biomarkers allows clinicians to evaluate treatment success and adjust therapy when necessary.[10]

Risk or Susceptibility Biomarkers.Risk biomarkers identify individuals who are at increased risk of developing a disease before symptoms appear.Examples include.Genetic mutations such as BRCA1/BRCA2, associated with breast and ovarian cancer risk.Elevated cholesterol levels as a risk factor for cardiovascular disease.Certain inflammatory markers linked to metabolic syndrome.These biomarkers are particularly important in preventive medicine and screening programs.[6]

Safety Biomarkers.Safety biomarkers indicate potential toxicity or adverse effects of treatment.For example.Liver enzymes (ALT, AST) to monitor drug-induced liver injury.Creatinine levels to assess kidney function during nephrotoxic therapy.They help ensure patient safety during long-term treatment.Overall Importance of Classification.The classification of biomarkers allows a structured approach to diagnosis, prognosis, treatment selection, and monitoring. In modern clinical laboratory medicine, multiple types of biomarkers are often used together to provide a comprehensive understanding of a patient's condition.With continuous advancements in genomics, proteomics, and metabolomics, new categories of biomarkers are being discovered, further expanding their role in precision medicine.[7]

Commonly Used Clinical Biomarkers.In clinical laboratory medicine, numerous biomarkers are routinely used for diagnosis, monitoring, and prognosis of diseases. These biomarkers are measured in blood, urine, or other biological fluids and provide essential information about organ function and pathological processes.[8]

Cardiac Biomarkers.Cardiac biomarkers are crucial in the diagnosis of cardiovascular diseases, particularly acute coronary syndromes.Troponin (cTnI and cTnT).Cardiac troponins are the gold standard biomarkers for diagnosing myocardial infarction (heart attack).Highly specific to cardiac muscle damage.Detectable within 3–6 hours after injury.Remain elevated for several days.Elevated troponin levels indicate myocardial cell damage and are essential for early intervention.CK-MB (Creatine Kinase-MB).Previously widely used for myocardial infarction diagnosis. Although less specific than troponin, it may help detect reinfarction.B-type Natriuretic Peptide (BNP).BNP and NT-proBNP are used to diagnose and monitor heart failure. Elevated levels reflect ventricular stress and fluid overload.[9]

Tumor Markers.Tumor markers are substances produced by cancer cells or by the body in response to cancer.PSA (Prostate-Specific Antigen).Used for screening and monitoring prostate cancer. Elevated PSA levels may indicate malignancy, inflammation, or benign enlargement.CA-125.Associated with ovarian cancer. It is mainly used for monitoring treatment response rather than initial diagnosis.AFP (Alpha-fetoprotein).Elevated in liver cancer (hepatocellular carcinoma) and some germ cell tumors.CEA (Carcinoembryonic Antigen).Used in colorectal cancer monitoring and assessing recurrence.Tumor markers are rarely sufficient alone for diagnosis but are valuable in combination with imaging and biopsy.[10]

Inflammatory Biomarkers.Inflammatory markers are widely used to detect infections and systemic inflammation.C-Reactive Protein (CRP).CRP is an acute-phase protein that increases during inflammation.Elevated in bacterial infections.Used in monitoring inflammatory diseases.High-sensitivity CRP (hs-CRP) is used in cardiovascular risk assessment.Procalcitonin (PCT).More specific for bacterial infections and sepsis. It helps differentiate bacterial from viral infections and guides antibiotic therapy.Erythrocyte Sedimentation Rate (ESR).An older but still useful marker of inflammation.[11]

Metabolic Biomarkers.Metabolic biomarkers are essential for diagnosing and monitoring chronic diseases.Glucose.Used to diagnose diabetes mellitus. Elevated fasting glucose levels indicate impaired glucose metabolism.HbA1c (Glycated Hemoglobin).Reflects average blood glucose levels over the previous 2–3 months.Essential for long-term diabetes monitoring.Indicates risk of complications.Lipid Profile.Includes total cholesterol, LDL, HDL, and triglycerides.Used to assess cardiovascular risk.[12]

Renal and Liver Function Biomarkers.Creatinine and Blood Urea Nitrogen (BUN).Used to assess kidney function. Elevated levels indicate renal impairment.ALT and AST.Liver enzymes that increase in liver damage, hepatitis, or drug toxicity. Bilirubin.Used to evaluate liver function and hemolytic disorders.Clinical Significance.These commonly used biomarkers form the foundation of routine laboratory testing worldwide. They provide objective, measurable data that guide clinical diagnosis, treatment decisions, and patient monitoring. In many cases, combining multiple biomarkers increases diagnostic accuracy and improves patient outcomes.[13]

Role of Biomarkers in Early Detection.Early detection of diseases significantly improves treatment success, reduces complications, and lowers mortality rates. Biomarkers play a fundamental role in identifying pathological processes before clinical symptoms become apparent. Their measurement in clinical laboratories allows for timely diagnosis and intervention.[20]

Early Detection of Cardiovascular Diseases.Cardiovascular diseases are one of the leading causes of death worldwide. Early detection through biomarkers has greatly improved patient survival.Cardiac troponins can detect myocardial injury even before significant ECG changes appear.High-sensitivity troponin assays allow detection of minimal cardiac damage at very early stages. hs-CRP (high-sensitivity C-reactive protein) helps identify individuals at increased risk of cardiovascular events, even when cholesterol levels are normal.BNP and NT-proBNP detect early heart failure before severe symptoms develop.Early biomarker testing enables prompt treatment and prevents irreversible heart damage[14]

Early Cancer Detection.Cancer is often asymptomatic in its initial stages. Biomarkers help identify malignancies earlier, improving prognosis.PSA screening may detect prostate cancer before symptoms appear.AFP may help identify early hepatocellular carcinoma in high-risk patients.CA-125 can support early detection of ovarian cancer in selected populations.Although tumor markers alone are not sufficient for definitive diagnosis, they serve as important screening and monitoring tools, especially in high-risk individuals.[15]

Early Diagnosis of Sepsis and Infections.Sepsis is a life-threatening condition that requires immediate diagnosis and treatment.Procalcitonin (PCT) rises rapidly in bacterial infections and helps identify sepsis at an early stage.CRP increases during acute inflammation.Molecular biomarkers can detect pathogens even before culture results are available.Early identification of infection reduces complications and mortality.[16]

Early Detection of Diabetes and Metabolic Disorders.Diabetes often develops silently over years.Fasting glucose and HbA1c allow detection of prediabetes and early-stage diabetes.Lipid profile abnormalities can indicate early cardiovascular risk in diabetic patients.Early metabolic screening prevents long-term complications such as nephropathy, neuropathy, and cardiovascular disease.Role in Preventive Medicine.Biomarkers are central to preventive healthcare strategies. [17]

Role of Biomarkers in Early Detection.Early detection of diseases significantly improves treatment success, reduces complications, and lowers mortality rates. Biomarkers play a fundamental role in identifying pathological processes before clinical symptoms become apparent. Their measurement in clinical laboratories allows for timely diagnosis and intervention.Early Detection of Cardiovascular Diseases.Cardiovascular diseases are one of the leading causes of death worldwide. Early detection through biomarkers has greatly improved patient survival.Cardiac troponins can detect myocardial injury even before significant ECG changes appear.High-sensitivity troponin assays allow detection of minimal cardiac damage at very early stages.[18]

hs-CRP (high-sensitivity C-reactive protein) helps identify individuals at increased risk of cardiovascular events, even when cholesterol levels are normal.BNP and NT-proBNP detect early heart failure before severe symptoms develop.Early biomarker testing enables prompt treatment and prevents irreversible heart damage.

Early Cancer Detection.Cancer is often asymptomatic in its initial stages. Biomarkers help identify malignancies earlier, improving prognosis.PSA screening may detect prostate cancer before symptoms appear.AFP may help identify early hepatocellular carcinoma in high-risk patients.CA-125 can support early detection of ovarian cancer in selected populations.Although tumor markers alone are not sufficient for definitive diagnosis, they serve as important screening and monitoring tools, especially in high-risk individuals.[19]

Early Diagnosis of Sepsis and Infections.Sepsis is a life-threatening condition that requires immediate diagnosis and treatment.Procalcitonin (PCT) rises rapidly in bacterial infections and helps identify sepsis at an early stage.CRP increases during acute inflammation.Molecular biomarkers can detect pathogens even before culture results are available.Early identification of infection reduces complications and mortality.Early Detection of Diabetes and Metabolic Disorders.Diabetes often develops silently over years.Fasting glucose and HbA1c allow detection of prediabetes and early-stage diabetes.Lipid profile abnormalities can indicate early cardiovascular risk in diabetic patients.Early metabolic screening prevents long-term complications such as nephropathy, neuropathy, and cardiovascular disease.[20]

Role in Preventive Medicine.Biomarkers are central to preventive healthcare strategies. Risk biomarkers, such as elevated cholesterol or genetic predisposition markers, help identify individuals who may benefit from lifestyle modifications or early medical intervention.Regular laboratory screening programs rely heavily on biomarker measurement to detect diseases before clinical manifestations occur.Clinical Importance.The use of biomarkers in early detection enhances diagnostic accuracy, supports rapid therapeutic decisions, and improves patient outcomes. With advances in technology, highly sensitive assays continue to improve the reliability of early diagnosis.[21]

Future Perspectives in Biomarker Research.The field of biomarkers is rapidly evolving, driven by advances in genomics, proteomics, metabolomics, and bioinformatics. Future developments promise to make biomarker testing even more sensitive, specific, and clinically relevant.

Genomic Biomarkers.Genomic biomarkers involve variations in DNA sequences that are associated with disease risk, progression, or response to therapy.Single Nucleotide Polymorphisms (SNPs) can predict susceptibility to cardiovascular diseases, diabetes, and cancer.Next-Generation Sequencing (NGS) allows simultaneous analysis of multiple genetic mutations, enabling early detection of hereditary diseases and cancer.Genomic biomarkers are central to personalized medicine, guiding targeted therapies and preventive interventions.[22]

Proteomic Biomarkers.Proteomics studies the entire protein content of cells, tissues, or fluids. Protein biomarkers can reflect real-time disease processes.Advanced mass spectrometry and protein microarrays enable the discovery of novel protein biomarkers.Proteomic biomarkers are increasingly used in oncology to detect tumor-specific proteins and monitor therapeutic response.Early detection of inflammatory or neurodegenerative disorders may also benefit from proteomic profiling.

Metabolomic Biomarkers.Metabolomics analyzes small molecules and metabolites in biological systems, providing a snapshot of physiological and pathological states.Metabolite patterns can detect early metabolic disorders, cardiovascular risk, and cancer metabolism.Integration with other biomarker data improves diagnostic accuracy and allows disease monitoring at the molecular level [23].

Integration with Personalized Medicine.The future of biomarker research lies in integrating genomic, proteomic, and metabolomic data to guide personalized treatment strategies.Combining multiple biomarkers enables precise disease risk assessment.Predictive biomarkers help tailor therapy for individual patients, improving efficacy and minimizing adverse effects.Real-time monitoring of biomarkers may allow dynamic adjustments of therapy.[24]

Emerging Technologies.Digital biomarker analysis using wearable devices and mobile health applications.Artificial intelligence and machine learning for biomarker data interpretation, pattern recognition, and predictive modeling.Point-of-care biomarker devices providing rapid, bedside diagnostics for early intervention.

Conclusion of Future Perspectives.Biomarker research is moving toward a more integrative and personalized approach. The combination of advanced technologies and multi-omics analysis promises earlier detection of diseases, improved treatment monitoring, and better preventive healthcare strategies. The continued evolution of biomarker discovery and application will play a central role in shaping the future of clinical laboratory medicine [25].

References:

1. Abduhakimov B. A. et al. Bolalar va o'smirlarda birlamchi tuberkulyozning o’ziga xos kechish xususiyatlari va klinik-laboratoriya usullari //Ta'lim innovatsiyasi va integratsiyasi. – 2024. – Т. 32. – №. 3. – С. 139-143.
2. Бердиярова Ш. Ш. и др. Клинико-лабораторная диагностика фолиевой кислотодефицитной анемии //TADQIQOTLAR. UZ. – 2024. – Т. 49. – №. 3. – С. 46-53.
3. Umarova T. A., Kudratova Z. E., Axmadova P. Role of conditionally pathogenic microflora in human life activities //Web of Medicine: Journal of Medicine, Practice and Nursing. – 2024. – Т. 2. – №. 11. – С. 29-32.
4. Muhamadiyeva L. A., Kudratova Z. E., Sirojeddinova S. Pastki nafas yo’llari patologiyasining rivojlanishida atipik mikrofloraning roli va zamonaviy diagnostikasi //Tadqiqotlar. Uz. – 2024. – Т. 37. – №. 3. – С. 135-139.
5. Umarova T. A., Kudratova Z. E., Norboyeva F. Modern aspects of etiology and epidemiology of giardias //Web of Medicine: Journal of Medicine, Practice and Nursing. – 2024. – Т. 2. – №. 11. – С. 25-28.
6. Isomadinova L. K., Daminov F. A. Glomerulonefrit kasalligida sitokinlar ahamiyati //Journal of new century innovations. – 2024. – Т. 49. – №. 2. – С. 117-120.
7. Umarova T. A., Kudratova Z. E., Maxmudova H. Mechanisms of infection by echinocococosis //Web of Medicine: Journal of Medicine, Practice and Nursing. – 2024. – Т. 2. – №. 11. – С. 18-21.
8. Даминов Ф. А., Исомадинова Л. К., Рашидов А. Этиопатогенгетические и клинико-лабораторные особенности сальмонелиоза //TADQIQOTLAR. UZ. – 2024. – Т. 49. – №. 3. – С. 61-67.
9. Umarova T. A., Kudratova Z. E., Baxromova M. Autoimmune diseases: new solutions in modern laboratory diagnostics //International Conference on Modern Science and Scientific Studies. – 2024. – С. 78-81.

10. Бердиярова Ш. Ш. и др. Узловой зоб и его клинико-лабораторная диагностика //TADQIQOTLAR. UZ. – 2024. – Т. 49. – №. 3. – С. 38-45.
11. Umarova T. A., Kudratova Z. E., Muhsinovna R. M. The main purpose of laboratory diagnosis in rheumatic diseases //International Conference on Modern Science and Scientific Studies. – 2024. – С. 82-85.
12. Umarova T. A., Kudratova Z. E., Ruxshona X. Contemporary concepts of chronic pancryatitis //International Conference on Modern Science and Scientific Studies. – 2024. – С. 11-15.
13. Хамидов З. З., Амонова Г. У., Исаев Х. Ж. Некоторые аспекты патоморфологии неспецифических язвенных колитов //Молодежь и медицинская наука в XXI веке. – 2019. – С. 76-76.
14. Umarova T. A., Kudratova Z. E., Muminova G. Instrumental diagnostic studies in chronic pancreatitis //International Conference on Modern Science and Scientific Studies. – 2024. – С. 16-20.
15. Атамурадовна М.Л., Рустамовна Р.Г., Эркиновна К.З. Роль современных биомаркеров в изучении различных поражений головного мозга //Достижения науки и образования. – 2020. – №. 10 (64). – С. 88-90.
16. Рустамова Г. Р., Мухамадиева Л. А. Современные аспекты клинико-лабораторных методов исследования острой ревматической лихорадки //International scientific review. – 2020. – №. LXVI. – С. 106-110.
17. Кудратова З.Е. и др. Роль цитокиновой регуляции при обструктивном синдроме атипичного генеза у детей // Анналы Румынского общества клеточной биологии. – 2021. – Т. 25. – №. 1. – С. 6279-6291.
18. Erkinovna K. Z. et al. Bronchial obstruction syndrome in young children with respiratory infections of different etiology: features of clinical manifestations and immune response //Проблемы науки. – 2021. – №. 1 (60). – С. 60-62.
19. Кудратова З.Е. и др. Хламидийные инфекции (внутриклеточная инфекция) в развитии бронхита // TJE-Tematics journal of Education ISSN. – 2021. – С. 2249-9822.
20. Kudratova Z. E. et al. Principles of therapy of chlamydial and mycoplasma infections at the present stage //Вопросы науки и образования. – 2021. – №. 28 (153). – С. 23-26.
21. Rustamova G. R., Kudratova Z. E. CHRONIC ENDOMETRITIS OLD ISSUES NEW POSSIBILITIES //Western European Journal of Medicine and Medical Science. – 2024. – Т. 2. – №. 5. – С. 12-14.
22. Erkinovna K. Z., Rustamovna R. G., Suratovna H. F. LABORATORY MARKERS OF PERINATAL HYPOXIC DAMAGE TO THE CENTRAL NERVOUS SYSTEM IN NEWBORNS //Наука, техника и образование. – 2020. – №. 10 (74). – С. 102-104.
23. Mukhamadieva L. A., Rustamova G. R., Kudratova Z. E. IMMEDIATE RESULTS OF COMPLEX TREATMENT OF CHILDREN WITH CHRONIC TONSILLITIS AND CHRONIC ADENOIDITIS ASSOCIATED WITH CMV AND EBV //Western European Journal of Medicine and Medical Science. – 2024. – Т. 2. – №. 5. – С. 20-24.
24. Umarova T. A., Kudratova Z. E., Norxujayeva A. Etiopathogenesis and modern laboratory diagnosis of prostatitis //International Conference on Modern Science and Scientific Studies. – 2024. – С. 6-10.